Jazz Pharmaceuticals plc has patented sulfonamides acting as orexin OX2 receptor agonists reported to be useful for the treatment of hypersomnia, narcolepsy and sleep disorders.
Debiopharm International SA has identified enoyl-(acyl-carrier protein) reductase FabI (Acinetobacter baumannii) inhibitors reported to be useful for the treatment of bacterial infections and hospital-acquired pneumonia.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has presented HBeAg (hepatitis B virus; HBV) and/or HBsAg (HBV) secretion inhibitors reported to be useful for the treatment of HBV infections.
National Institute of Pharmaceutical R&D Co. Ltd. has discovered compounds with ability to capture reactive carbonyl species reported to be useful for the treatment of eye disorders, among others.
Fochon Biosciences Ltd. has disclosed mitogen-activated protein kinase (ERK) inhibitors, particularly ERK1 and/or ERK2 reported to be useful for the treatment of cancer.
University of Maryland has identified proteolysis targeting chimeras (PROTACs) acting as apoptosis regulator Bcl-2, Bcl-2-like protein 1 (BCL2L1) and induced myeloid leukemia cell differentiation protein Mcl-1 degradation inducers.
Carrick Therapeutics UK Ltd. has synthesized cyclin-dependent kinase 12 (CDK12) and/or cyclin-dependent kinase 7 (CDK7) inhibitors reported to be useful for the treatment of autoimmune diseases, cardiovascular disorders, fragile X syndrome, muscular dystrophy, neurodegeneration, renal disorders and cancer.
Shanghai Leadopharma Technology Co. Ltd. has presented transient receptor potential cation channel subfamily A member 1 (TRPA1) antagonists reported to be useful for the treatment of irritable bowel syndrome, Crohn's disease, ulcerative colitis, pain and inflammation.
Scorpion Therapeutics Inc. has disclosed urea derivatives acting as phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer.
RSS
